Research Brief

Screening for COVID-19: Patient factors predicting positive PCR test

Douglas W. Challener MD1-3, Gregory J. Challener MD2, Vanessa J. Gow-Lee MD2, Madiha Fida MBBS1, Aditya S. Shah MBBS1 and John C. O’Horo MD, MPH1-3

1Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota; 2Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota; and 3Division of Pulmonary and Critical Care Medicine, Rochester, Minnesota

Abstract

To inform the efficient allocation of testing resources, we evaluated the characteristics of those tested for COVID-19 to determine predictors of a positive test. Recent travel and exposure to a confirmed case were both highly predictive of positive testing. Symptom-based screening strategies alone may be inadequate to control the ongoing pandemic.

Methods

At the Mayo Clinic in Rochester, Minnesota, we began screening patients for COVID-19 on a large scale on March 12, 2020, after Minnesota’s first case was reported on March 10, 2020. Patients who were screened were given a standardized questionnaire by a nurse prior to testing. This questionnaire included questions about patient symptoms such as fever (subjective or objective), cough, shortness of breath, and medical comorbidities. The patients were also asked about recent travel as well as exposure to laboratory-confirmed cases of COVID-19.

We examined the medical records of patients with the first 48 positive tests and a selection of 98 patients with negative tests. The COVID-19–negative patients were selected in a random fashion by matching age (±5 years), sex, collection date, and testing location (Minnesota, Wisconsin, or Arizona) with the positive patients.

Results

Each positive patient had at least a single negative control. All patients were screened between March 12 and March 26, 2020. The chart of each patient was then manually abstracted by a physician to identify patient characteristics, symptoms, and potential exposures identified by the nurse triage line as reasons to recommend screening prior to each individual’s test date. Travel to a major metropolitan area was also recorded. Study data were collected and managed using REDCap electronic data capture tools hosted at the Mayo Clinic. Descriptive statistics, t-tests, and logistic regression analysis were performed using JMP version 14 software (SAS Institute, Cary, NC). Our institutional review board approved this study.

The average age in the cohort was 46 years, with slightly more men than women (Table 1). Due to the matching strategy for negative controls, there was no statistically significant difference between the 2 groups. Patients with both negative and positive tests had high rates of fever and cough, which likely led to the initial decision to screen them. Overall, the cohort had few medical comorbidities.

The largest differentiating factors between the patients with positive and negative tests were exposures. Patients with positive tests were significantly more likely to have travelled to a major metropolitan area within the preceding 2 weeks or to have come into contact with a person with laboratory-confirmed COVID-19. In a multivariable logistic regression model predicting a positive test adjusted for these 2 factors, close contact with a confirmed case increased the odds of a positive test by 17 times (95% CI, 4.6–88.4), and recent travel increased the odds of a positive test by 4.7 times (95% CI, 1.9–12.7).

Discussion

The selection of patients for SARS-CoV-2 screening remains challenging. Many factors influence the decisions on which patients to screen, including testing resources, test characteristics (sensitivity and specificity), and local disease prevalence. The challenge in
determining the appropriate patients to screen has been apparent; the CDC has revised its guidance several times. This study investigates the results of testing ambulatory patients in a relatively low prevalence area in early March 2020 and suggests that exposure to the disease is more predictive of a positive test than any examined symptom.

This retrospective analysis of the initial phase of our screening for COVID-19 had several strengths. A rigorous physician review of each medical record helped ensure accurate capture of patient information. Additionally, the short study period helped limit any major local factors that could have affected the results, such as changing screening guidelines or increasing community prevalence. Furthermore, all the tests were collected, transported, and analyzed within the same internal institutional laboratory process.

This study also had several limitations. First, this was a retrospective analysis; thus, it may have suffered from selection bias affecting the participants. To help avert this bias, our negative prospective analysis; thus, it may have suffered from selection bias. Furthermore, all the tests were collected, transported, and analyzed as changing screening guidelines or increasing community prevalence. In the effort to contain the pandemic, there may be a role for testing patients with these risk factors regardless of symptom presence.

Acknowledgments. None.

Financial support. No financial support was provided relevant to this article.

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
2. Shah A, Kashyap R, Tosh P, Sampathkumar P, O’Horo JC. Guide to understanding the 2019 novel coronavirus. Mayo Clin Proc 2020;95:646–52.
3. Gostic K, Gomez ACR, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. Elife 2020;9:e55570.
4. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the Icelandic population. New Engl J Med 2020 Apr 14 [Epub ahead of print]. doi: 10.1056/NEJMoa2006100.
5. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus (2019-nCoV) infections among passengers on evacuation flights. MedRxiv 2020. doi: 10.1101/2020.02.03.20020248.
6. Rodino KG, Espy MJ, Buckwalter SP, et al. Evaluation of saline, phosphate buffered saline and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing. J Clin Microbiol 2020 Mar 30 [Epub ahead of print]. doi: 10.1128/JCM.00390-20.
7. Shah A, Challener D, Tande AJ, et al. Drive through testing: a unique, efficient method of collecting large volume of specimens during the SARS-CoV-2 (COVID-19) pandemic. Mayo Clin Proc 2020. doi: 10.1016/j.mayocp.2020.04.030.
8. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377–81.

Table 1. Characteristics of Patients Who Were Tested for COVID-19

| Characteristic                      | Positive Test (n=48), No. (%) | Negative Test (n=98), No. (%) | P Value |
|-------------------------------------|------------------------------|------------------------------|---------|
| Age, mean y (SD)                    | 45.9 (19.0)                  | 46.0 (16.0)                  | .98     |
| Sex, male                           | 26 (54)                      | 61 (62)                      | .37     |
| Healthcare worker                   | 12 (25)                      | 19 (20)                      | .94     |
| Iatrogenic immunocompromise          | 2 (4.4)                      | 5 (5.1)                      | 1       |
| Chronic pulmonary disease (asthma, COPD, or ILD) | 6 (13)                      | 30 (31)                      | .02     |
| Congestive heart failure            | 1 (2)                        | 4 (4)                        | .57     |
| End-stage renal disease             | 0 (0)                        | 1 (1)                        | .99     |
| End-stage liver disease             | 0 (0)                        | 0 (0)                        | 1       |
| Close exposure to lab-confirmed case of COVID-19 | 13 (29.5)                  | 5 (5.6)                      | <.01    |
| Recent travel to major metropolitan area | 33 (73)                      | 38 (44)                      | <.01    |
| Cough                               | 42 (93)                      | 92 (94)                      | .90     |
| Fever                               | 36 (80)                      | 83 (86)                      | .33     |

Note. COVID-19, novel coronavirus 2019; SD, standard deviation; COPD, chronic obstructive pulmonary disease; ILD, interstitial lung disease.

Outpatient Clostridioides difficile infections: An opportunity for antimicrobial stewardship programs

Austin R. Morrison PharmD1, Rachel M. Kenney PharmD, BCIDP2 and Susan L. Davis PharmD, FIDP1,2

1Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan and 2Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan

Author for correspondence: Rachel Kenney, E-mail: rkenney1@hfhs.org

Cite this article: Morrison AR, Kenney RM, and Davis SL. (2020). Outpatient Clostridioides difficile infections: An opportunity for antimicrobial stewardship programs. Infection Control & Hospital Epidemiology. 41: 969–971. https://doi.org/10.1017/ice.2020.199

© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Approximately 34% of adult Clostridioides difficile infections (CDIs) are community associated, and possibly many more are underdiagnosed or underreported.1,2 Although many health